SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
PFNX
--
0.00%
--
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfenex Inc. - PFNX
NEW YORK, June 03, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Pfenex Inc. (“Pfenex” or the “Company”) (NYSE: PFNX)   Such investors are advised to.
GlobeNewswire · 1d ago
Oppenheimer Maintains Outperform on Pfenex, Raises Price Target to $10
Oppenheimer maintains Pfenex (AMEX:PFNX) with a Outperform and raises the price target from $9 to $10.
Benzinga · 3d ago
Pfenex Inc. Shareholders Who Have Suffered Losses Greater Than $50K Encouraged To Contact Kehoe Law Firm, P.C.
GlobeNewswire · 05/27 17:23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfenex Inc. - PFNX
NEW YORK, May 27, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Pfenex Inc. (“Pfenex” or the “Company”) (NYSE: PFNX). Such investors are advised to.
GlobeNewswire · 05/27 13:17
Edited Transcript of PFNX earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/26 14:00
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfenex Inc. - PFNX
NEW YORK, NY / ACCESSWIRE / May 25, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Pfenex Inc. ("Pfenex" or the "Company") (NYSE:PFNX) Such investors are advised ...
ACCESSWIRE · 05/25 19:50
Pfenex Inc. (NYSEMKT:PFNX) Analysts Are Reducing Their Forecasts For This Year
Simply Wall St. · 05/18 12:21
SunTrust Robinson Humphrey Maintains Buy on Pfenex, Lowers Price Target to $13
SunTrust Robinson Humphrey maintains Pfenex (AMEX:PFNX) with a Buy and lowers the price target from $15 to $13.
Benzinga · 05/12 13:23
Pfenex's (PFNX) CEO Eef Schimmelpennink on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 15:26
Pfenex Reports First Quarter 2020 Results and Provides Business Update
GlobeNewswire · 05/07 21:05
Pfenex Q1 EPS $(0.310) Misses $(0.240) Estimate, Sales $682.000K Down From $7.862M YoY
Pfenex (AMEX:PFNX) reported quarterly losses of $(0.310) per share which missed the analyst consensus estimate of $(0.240) by 29.17 percent. This is a 158.33 percent decrease over losses of $(0.120) per share from the
Benzinga · 05/07 20:57
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfenex Inc. - PFNX
GlobeNewswire · 05/05 23:15
Pfenex to Announce First Quarter 2020 Financial Results on May 7
GlobeNewswire · 04/24 21:05
Two shops cut views on Biogen as hopes for Alzheimer's med fade
Seeking Alpha - Article · 04/23 11:13
Oppenheimer Initiates Coverage On Pfenex with Outperform Rating, Announces Price Target to $9
Oppenheimer analyst Esther Rajavelu initiates coverage on Pfenex (AMEX:PFNX) with a Outperform rating and announces Price Target to $9.
Benzinga · 04/23 10:27
PFNX INVESTIGATION: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Investigation of Pfenex Inc.
PR Newswire · 04/17 15:00
Pfenex Inc. (NYSEMKT:PFNX) Analysts Just Slashed This Year's Estimates
Simply Wall St. · 04/16 18:18
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfenex Inc. - PFNX
GlobeNewswire · 04/16 14:55
Mid-Afternoon Market Update: Dow Falls 1.5%; Pfenex Shares Plummet
Toward the end of trading Wednesday, the Dow traded down 1.5% to 23589.88 while the NASDAQ fell 0.98% to 8,432.13. The S&P also fell, dropping 1.78% to 2,795.28.
Benzinga · 04/15 18:38